References
1. Cesaro S, Tridello G, Castagnola E, et al. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients.Eur J Haematol. 2017;99(3):240-248. doi: 10.1111/ejh.12910
2. Kobayashi R, Hori D, Sano H, Suzuki D, Kishimoto K, Kobayashi K. Risk Factors for Invasive Fungal Infection in Children and Adolescents With Hematologic and Malignant Diseases: A 10-year Analysis in a Single Institute in Japan. Pediatr Infect Dis J.2018;37(12):1282-1285.
3. Puia-Dumitrescu M, Smith PB. Antifungal Drugs in Newborns and Children. Pediatr Clin North Am. 2017;64(6):1389-1402. doi: 10.1016/j.pcl.2017.08.013.
4. Ramos-Martín V, O’Connor O, Hope W. Clinical pharmacology of antifungal agents in pediatrics: children are not small adults.Curr Opin Pharmacol. 2015;24:128-34. doi: 10.1016/j.coph.2015.08.009.
5. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 2010;24(2):51-61. doi: 10.1016/j.blre.2009.11.003.
6. Candoni A, Caira M, Cesaro S, et al; SEIFEM GROUP (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne). Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.Mycoses. 2014;57(6):342-50. doi: 10.1111/myc.12161.
7. Day JN, Chau IT, Lalloo DG. Combination antifungal therapy for Cryptococcal Meningitis. N Engl J Med. 2013;368:2522–3.
8. Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer. 2010;116(22):5290-6. doi: 10.1002/cncr.25312.
9. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.Antimicrob Agents Chemother. 2005;49:3697–701.
10. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52:1556–8.
11. Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis.Antimicrob Agents Chemother. 2006;50:1567–9.
12.Cesaro S, Giacchino M, Locatelli F, Spiller M, Buldini B, Castellini C, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis. 2007;7:28.
13.Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents.2015;45(3):283-8. doi: 10.1016/j.ijantimicag.2014.08.012.
14.Wattier RL, Dvorak CC, Hoffman JA,Brozovich AA, Bin-Hussain I, Groll AH, et al. A Prospective, International Cohort Study of Invasive Mold Infections in Children. J Pediatric Infect Dis Soc.2015;4(4):313-22. doi: 10.1093/jpids/piu074
15.Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Inern Med. 2015;162(2):81-9. doi: 10.7326/M13-2508.
16. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-83.
17. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327-40.
18.Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi: 10.1093/cid/ciw326.
19. Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia.Blood Res. 2017;52(3):167-173.
20. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96:748-57.
21. Georgiadou SP, Pongas G, Fitzgerald NE, Lewis RE, Rytting M, Marom EM, Kontoyiannis DP. Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study.J Pediatric Infect Dis Soc. 2012 Jun;1(2):125-35. 22. Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.Int J Antimicrob Agents.  2015;45(3):283-8.
23. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.Antimicrob Agents Chemother. 2002;46:3039–41.
24. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187:1834–43.
25. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis.2004;39:797–802.
26. Groll AH, Silling G, Young C, Schwerdtfeger R, Ostermann H, Heinz WJ, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother.2010;54(10):4143-9. doi: 10.1128/AAC.00425-10.
Table 1. Demographic and clinical characteristics of the patients, and data for IFI episodes.